Navigation Links
OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
Date:5/11/2009

BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final survival data from a randomized Phase 2 trial evaluating OGX-011 in combination with docetaxel versus docetaxel alone as first-line chemotherapy in patients with metastatic castration-resistant prostate cancer will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, Phase 1 clinical data evaluating OncoGenex' second product candidate, OGX-427, will also be featured in an oral presentation at ASCO.

Abstracts will be made available to the public online on ASCO's website, www.ASCO.org, on Thursday, May 14 at 6:00 p.m. (EDT).

The oral presentations are scheduled for Saturday, May 30 at the ASCO meeting in Orlando, Florida. These formal presentations will also include new data that has been updated since abstracts were submitted to ASCO.

Abstract Presentation Information

    Title:    Mature results of a randomized phase II study of OGX-011 in
              combination with docetaxel/prednisone versus
              docetaxel/prednisone in patients with metastatic castration
              resistant prostate cancer
    Authors:  K. N. Chi, S. J. Hotte, E. Yu, D. Tu, B. Eigl, I. Tannock,
              F. Saad, S. North, J. Powers, E. Eisenhauer, National Cancer
              Institute of Canada Clinical Trials Group
    Date:     4:30 p.m. - 4:45 p.m. EDT, Saturday, May 30, 2009
    Location: Level 3, Chapin Theatre, W320, Orange County Convention Center
    Abstract: # 5012

    Title:    OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO),
              against HSP27: Results of a first-in-human trial
    Authors:  S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S. H
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports First Quarter Financial Results
2. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
3. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
5. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
6. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
7. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
8. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
9. OncoGenex Reports Third Quarter Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
11. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... developed by researchers at the USC Viterbi School ... a 3-D microfluidic system quickly and cheaply by ... , Microfluidic systems are used in many fields ... small volumes of fluids for use in applications ... clinical diagnostic testing, and synthetic chemistry. Traditionally, microfluidic ...
(Date:9/22/2014)... Analysis of circulating tumor cells (CTCs) in a mouse ... expression in several groups of CTCs, including significant differences ... ability to generate metastases. In their study reported ... , investigators from the Massachusetts General Hospital (MGH) Cancer ... found unexpected factors that may prove to be targets ...
(Date:9/22/2014)... engineering researchers have developed a unique nanoscale device ... of light. The discovery could have major implications ... for computation and communication. , The research paper ... assistant professor Mo Li and his graduate student ... appear in the October issue of Nature ...
(Date:9/22/2014)... September 22, 2014 Lawrence Livermore ... John DeGioia on Friday renewed their institutional commitment ... additional five years to expand the collaborative work ... and global climate, energy and environmental sciences. , ... MOU originally signed in December 2009 and is ...
Breaking Biology Technology:Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Engineers show light can play seesaw at the nanoscale 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2
... Md. and BEIJING, Jan. 10, 2012 The global ... as Aeras and the China National Biotec Group (CNBG) ... develop new tuberculosis (TB) vaccines. The agreement between the ... largest biotechnology corporation in China signals a commitment by ...
... A superlens would let you see a virus in a drop ... It might, says Durdu Guney, make ultra-high-resolution microscopes as commonplace as ... a superlens, also known as a perfect lens, though people are ... so-called diffraction limit, so even the best won,t usually let us ...
... . , Scientists at Universidad Carlos III ... have joined efforts to develop new materials for thermonuclear ... oxide dispersion-strengthened, reduced-activation steel for the reactor structure. , ... the current energy crisis. It is produced when ...
Cached Biology Technology:Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 2Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 3Almost perfect: A breakthrough in superlens development 2New material for thermonuclear fusion reactors 2New material for thermonuclear fusion reactors 3
(Date:9/23/2014)... whose turn it is to do the washing up, negotiating ... as many students returning to university for the new ... a house can be a tricky business. , And now ... that new technology to allow people to monitor their energy ... the tension. , The study by a team of technology ...
(Date:9/23/2014)... California , 23 de septiembre de ... lanzamiento del Sistema 1290 Infinity II LC, ... de Infinity en su portafolio de cromatografía ... científicos y directores de laboratorio que alcancen ... excepcional, facilidad de uso y capacidad de ...
(Date:9/22/2014)... 2014 A new American Cancer Society study suggests ... (SNAP), previously known as the food stamp program, ... eligible non-participants. The authors say the findings emphasize ... the dietary quality of SNAP participants. , The ... households with the resources to obtain a nutritionally ...
Breaking Biology News(10 mins):Smart meters could cause conflict for housemates, study shows 2Smart meters could cause conflict for housemates, study shows 3Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3Federal food program puts food on the table, but dietary quality could be improved 2
... by the Smithsonian Institution has completed a new study ... a 3-foot-tall, 18,000-year-old hominin skeleton, discovered four years ago ... one of the most striking confirmations of the original ... one of the oldest human migrations to Asia. The ...
... 20, 2007) Fifteen students mentored by members of the ... receive the 2007ASPB Summer Undergraduate Research Fellowships (SURF). The ... to his or her research project for a 10-week ... to the mentor for lab supplies, a free student ...
... virus first struck New York City in 1999, news ... health officials alike, showing that even affluent, urban societies ... has been widely studied, there is still little known ... urban and rural areas. Assistant professor at the ...
Cached Biology News:New research sheds light on 'Hobbit' 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 3UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC 2
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
ASCIZ...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
...
Biology Products: